Ordaōs Raises $5 Million in Seed to Accelerate Drug Design and Discovery – QNT Press Release

Ordaōs creates novel mini-proteins that help pharma and biotechs around the world deliver safer and more effective life-saving treatments in a fraction of the time of traditional discovery methods.

NEW YORK, Aug. 25, 2022 /PRNewswire/ — Ordaōs, a biotechnology company designing novel mini-proteins to help drug hunters deliver life-saving treatments, today announced the completion of $5M in seed financing to aid in new product development and expand partner acquisition efforts. The oversubscribed round was led by Middleland Capital’s VTC Ventures with additional investments from Route 66 Ventures, Banyan Pacific Capital, IAG Capital Partners, and Citta Capital. Ordaōs is a human- enabled, machine-driven drug design company that leverages proprietary multitask meta-learning and reinforcement learning to create mini-proteins that enable targeted therapies to reduce patient suffering, improve health, and extend life.

Full story available on Benzinga.com

Source link

Recommended For You

About the Author: News Center